Utilize este identificador para referenciar este registo: http://hdl.handle.net/10451/32818
Registo completo
Campo DCValorIdioma
degois.publication.firstPage1399pt_PT
degois.publication.issue5pt_PT
degois.publication.lastPage1419pt_PT
degois.publication.titleBrainpt_PT
dc.relation.publisherversionhttps://academic.oup.com/brainpt_PT
dc.contributor.authorMiranda, Hugo Vicente-
dc.contributor.authorSzego, Éva M.-
dc.contributor.authorOliveira, Luís M. A.-
dc.contributor.authorBreda, Carlo-
dc.contributor.authorDarendelioglu, Ekrem-
dc.contributor.authorOliveira, Rita M. de-
dc.contributor.authorFerreira, Diana G.-
dc.contributor.authorGomes, Marcos A.-
dc.contributor.authorRott, Ruth-
dc.contributor.authorOliveira, Márcia-
dc.contributor.authorMunari, Francesca-
dc.contributor.authorEnguita, Francisco J.-
dc.contributor.authorSimões, Tânia-
dc.contributor.authorRodrigues, Eva F.-
dc.contributor.authorHeinrich, Michael-
dc.contributor.authorMartins, Ivo C.-
dc.contributor.authorZamolo, Irina-
dc.contributor.authorRiess, Olaf-
dc.contributor.authorCordeiro, Carlos-
dc.contributor.authorFreire, Ana Ponces-
dc.contributor.authorLashuel, Hilal A.-
dc.contributor.authorSantos, Nuno C.-
dc.contributor.authorLopes, Luisa V.-
dc.contributor.authorXiang, Wei-
dc.contributor.authorJovin, Thomas M.-
dc.contributor.authorPenque, Deborah-
dc.contributor.authorEngelender, Simone-
dc.contributor.authorZweckstetter, Markus-
dc.contributor.authorKlucken, Jochen-
dc.contributor.authorGiorgini, Flaviano-
dc.contributor.authorQuintas, Alexandre-
dc.contributor.authorOuteiro, Tiago F.-
dc.date.accessioned2018-04-16T13:48:23Z-
dc.date.available2018-04-16T13:48:23Z-
dc.date.issued2017-
dc.identifier.citationBrain 2017: 140; 1399–1419pt_PT
dc.identifier.issn0006-8950-
dc.identifier.urihttp://hdl.handle.net/10451/32818-
dc.description© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.pt_PT
dc.description.abstractα-Synuclein misfolding and aggregation is a hallmark in Parkinson's disease and in several other neurodegenerative diseases known as synucleinopathies. The toxic properties of α-synuclein are conserved from yeast to man, but the precise underpinnings of the cellular pathologies associated are still elusive, complicating the development of effective therapeutic strategies. Combining molecular genetics with target-based approaches, we established that glycation, an unavoidable age-associated post-translational modification, enhanced α-synuclein toxicity in vitro and in vivo, in Drosophila and in mice. Glycation affected primarily the N-terminal region of α-synuclein, reducing membrane binding, impaired the clearance of α-synuclein, and promoted the accumulation of toxic oligomers that impaired neuronal synaptic transmission. Strikingly, using glycation inhibitors, we demonstrated that normal clearance of α-synuclein was re-established, aggregation was reduced, and motor phenotypes in Drosophila were alleviated. Altogether, our study demonstrates glycation constitutes a novel drug target that can be explored in synucleinopathies as well as in other neurodegenerative conditionspt_PT
dc.description.sponsorshipAuthors were supported by: H.V.M. (Fundação para a Ciência e Tecnologia (FCT), Portugal SFRH/BPD/64702/ 2009 and SFRH/BPD/109347/2015; EU FP7 project MEFOPA), L.M.A.O (FCT - SFRH/BD/23604/2005; CIRM-BMFB joint grant, 315050 AZ0101-31P6855), R.M.O. and T.S. (FCT SFRH/BPD/41416/2007; SFRH/ BPD/31209/2006); W.X. (Deutsche Forschungsgemeinschaft, SFB539/A3); C.B. and F.G. (Parkinson’s UK and the Medical Research Council, UK). S.E. is supported by Israel Academy of Sciences, Rappaport Family Institute for Research in the Medical Sciences, The Allen and Jewel Prince Center for Neurodegenerative Disorders of the Brain. T.F.O. (EMBO Installation Grant; Marie Curie IRG, Neurofold; DFG Center for Nanoscale Microscopy and Molecular Physiology of the Brain; I.C.M. (FCT SFRH/BPD/74287/2010; Investigador FCT IF/00772/ 2013). This work was supported by: FCT PTDC/SAUNEU/105215/2008, PTDC/QUI/73430/2006, PTDC/SAUENB/117013/2010, PTDC/NEU-OSD/5644/2014; EU FP7 project MEFOPA; CIRM-BMFB joint grant (315050 AZ0101-31P6855); Max Planck Society; and European Union (NEURASYNC PITNGA-2009-238316).pt_PT
dc.language.isoengpt_PT
dc.publisherOxford University Presspt_PT
dc.relationSFRH/BPD/64702/ 2009pt_PT
dc.relationSFRH/BPD/109347/2015pt_PT
dc.relationSFRH/BD/23604/2005pt_PT
dc.relationSFRH/BPD/41416/2007pt_PT
dc.relationSFRH/ BPD/31209/2006pt_PT
dc.relationSFRH/BPD/74287/2010pt_PT
dc.relationIF/00772/ 2013pt_PT
dc.relationPTDC/SAUNEU/105215/2008pt_PT
dc.relationPTDC/QUI/73430/2006pt_PT
dc.relationPTDC/SAUENB/117013/2010pt_PT
dc.relationPTDC/NEU-OSD/5644/2014pt_PT
dc.relationNEURASYNC PITNGA-2009-238316pt_PT
dc.rightsrestrictedAccesspt_PT
dc.subjectGlycationpt_PT
dc.subjectParkinson’s diseasept_PT
dc.subjectNeurodegenerationpt_PT
dc.subjectAlpha-synucleinpt_PT
dc.titleGlycation potentiates α-synuclein-associated neurodegeneration in synucleinopathiespt_PT
dc.typearticlept_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.peerreviewedyespt_PT
degois.publication.volume140pt_PT
dc.identifier.doi10.1093/brain/awx056pt_PT
Aparece nas colecções:IMM - Artigos em Revistas Internacionais

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Glycation_potentiates.pdf1,84 MBAdobe PDFVer/Abrir    Acesso Restrito. Solicitar cópia ao autor!


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.